Stay updated on CABozantinib in NSCLC MET Clinical Trial
Sign up to get notified when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.

Latest updates to the CABozantinib in NSCLC MET Clinical Trial page
- Check5 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study record content. Access to the study details is blocked and the expected content is not visible.SummaryDifference19%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedNo additions or deletions were provided in the site changes data, so there is no update to report for this page.SummaryDifference0.0%

- Check27 days agoChange DetectedThe revision number changes from v3.6.5 to v3.6.6, indicating a small update to the page. This update appears to affect backend or formatting aspects rather than the study content.SummaryDifference0.0%

- Check48 days agoChange DetectedA new revision label, v3.6.5, has been applied, replacing the previous v3.6.4. This update appears to be a routine site maintenance or software/version bump and does not indicate changes to the study text, eligibility criteria, or participant information.SummaryDifference0.0%

- Check62 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4 on the page. It represents a small backend/frontend update without altering displayed study details.SummaryDifference0.0%

- Check84 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing the previous Revision: v3.6.2. This appears to be a backend or formatting update and does not modify study details or public content.SummaryDifference0.0%

Stay in the know with updates to CABozantinib in NSCLC MET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.